MESO · Mesoblast Ltd · Documents
$15.67
+2.28 (+17.03%)
At close · Oct 29
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$1.74B
Shares
129.85M
Volume · Oct 29
696.52K
Avg daily vol (3M)
231.29K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | — | 2026-10-29 | — | |
| 6-K | Mesoblast reported a 44% increase in Ryoncil net revenue to US$28 million and an 85% improvement in net operating cash spend to US$2.3 million for the first fiscal quarter 2026, with US$99 million cash at September 30, 2026. | 2026-10-16 | — | |
| 6-K | Mesoblast Limited reported new issue and cessation-of-securities notices, notification of issue, conversion or payment of unquoted equity securities, and an application for securities quotation to the Australian Securities Exchange on October 14, 2026. | 2026-10-15 | 2026-10-14 | |
| 6-K | Mesoblast Limited reported FY2026 revenue of US$120.3 million versus US$17.2 million in FY2025, Ryoncil net product revenue of US$115.2 million, cash reserves of US$102.9 million, and treatment completion for 350 patients in its pivotal rexlemestrocel-L trial. | 2026-10-13 | — | |
| 6-K | Mesoblast Limited received FDA approval for the T-cell Proliferation Inhibition Bioassay (TIBA), which will monitor potency and release stability for new commercial Ryoncil lots alongside IL-2Rα inhibition and CAP assays. | 2026-09-24 | — | |
| 6-K | — | 2026-08-27 | — | |
| 20-F | — | 2026-08-27 | 2026-06-30 | |
| 6-K | — | 2026-08-25 | — | |
| 6-K | — | 2026-08-24 | — | |
| 6-K | — | 2026-08-18 | 2026-08-17 | |
| 6-K | — | 2026-07-30 | — | |
| 6-K | — | 2026-07-21 | — | |
| 6-K | — | 2026-07-15 | 2026-07-14 | |
| 6-K | — | 2026-07-14 | — | |
| 6-K | — | 2026-07-10 | — | |
| 6-K | — | 2026-07-01 | — | |
| 6-K | — | 2026-06-25 | — | |
| 6-K | — | 2026-06-10 | — | |
| 6-K | — | 2026-04-30 | — | |
| 6-K | — | 2026-04-29 | — | |
| 6-K | — | 2026-04-17 | — | |
| 6-K | — | 2026-04-15 | — | |
| 6-K | — | 2026-04-08 | — | |
| 6-K | — | 2026-04-08 | — | |
| 6-K | — | 2026-04-08 | — | |
| 6-K | — | 2026-04-08 | — | |
| 6-K | — | 2026-03-23 | — | |
| 6-K | — | 2026-03-18 | — | |
| 6-K | — | 2026-03-13 | 2026-03-12 | |
| 6-K | — | 2026-03-12 | — | |
| 6-K | — | 2026-02-27 | — | |
| 6-K | — | 2026-02-27 | 2025-12-31 | |
| 6-K | — | 2026-02-23 | — | |
| 6-K | — | 2026-02-12 | — | |
| 6-K | — | 2026-01-29 | — | |
| 6-K | — | 2026-01-28 | — | |
| 6-K | — | 2026-01-21 | 2026-01-19 | |
| 6-K | — | 2026-01-16 | — | |
| 6-K | — | 2026-01-14 | — | |
| 6-K | — | 2026-01-13 | 2026-01-12 | |
| 6-K | — | 2026-01-09 | — | |
| 6-K | — | 2026-01-07 | — | |
| 6-K | — | 2026-01-02 | — | |
| F-3ASR | — | 2025-12-31 | — | |
| F-3 | — | 2025-12-30 | — | |
| 6-K | — | 2025-12-30 | — | |
| 6-K | — | 2025-12-29 | 2025-12-24 | |
| 6-K | — | 2025-12-18 | 2025-12-17 | |
| 6-K | — | 2025-12-12 | — | |
| 6-K | — | 2025-12-04 | — |
Showing 1–50 of 292 filings
Key facts
CIK
1345099
CUSIP
590717401
13F (30d)
12 filings
12 filers
Visit website
Investor relations